TCR Design Construction and Plasmid GLP Production

As a leading provider of customized services, Creative Biolabs devotes to the development of T cell therapy, such as T cell receptor (TCR) gene therapy. Through altering the specificity of T cell receptors (TCR), T cells can be genetically modified to enhance their tumor-killing activity, which is considered as a fascinating approach. Undoubtedly, Creative Biolabs offers products and services for T cells modified by TCR.

TCR recognizes the tumor.Fig.1 TCR recognizes the tumor.

Affinity Enhanced TCR Service

CAR-T technology, through a series of cooperative procedures, finally meets the requirements of FDA for cell therapy (Fig.2). It is also imperative for us to provide high-affinity TCR, and increase the sensitivity and specificity of antigen recognition. High-affinity TCR can be achieved by Creative Biolabs in several ways:

TCR Gene Transduction System Service

Creative Biolabs is a leader in the field of genetically engineered T cells for cancer treatment, providing gene transduction system service for the generation of TCR-modified T cells. With our advanced technology and rich experience, we provide the most professional carrier service for the cutting-edge transgenic immunotherapy.

Manufacturing and delivery pipeline of genetically modified T-cell therapies.Fig.2 Manufacturing and delivery pipeline of genetically modified T-cell therapies

Our GLP Plasmid Production Service

Based on the general approach of TCR construction, Creative Biolabs provides an optimized TCR carrier production method.

Highlights

Creative Biolabs scientists are committed to being a reliable partner of your TCR design construction and GLP plasmid production and providing the most efficient solution for your project. Tell us what you need and we will provide a guide to project cost estimates and timelines.

Please contact us and our team will get back to you as soon as possible.

References

  1. Heslop, Helen E. "Genetic engineering of T-cell receptors: TCR takes to titin." Blood, The Journal of the American Society of Hematology 122.6 (2013): 853-854.
  2. Sharpe, M., and N. Mount. "Genetically modified T cells in cancer therapy: opportunities and challenges. Dis Model Mech. 2015; 8: 337–50."

For Research Use Only | Not For Clinical Use

Online Inquiry
Copyright © 2024 Creative Biolabs. All Rights Reserved.
ISO 9001 Certified - Creative Biolabs Quality Management System.